Orlistat Polpharma

Orlistat, the active ingredient in Orlistat Polpharma, is a lipase inhibitor presented as a oral tablet for oral use. It treats obesity and overweight in adults when used with a reduced‑calorie diet and lifestyle changes.

GNH USA supplies Orlistat Polpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orlistat Polpharma is indicated for conditions that involve excess body weight and works within the gastrointestinal fat‑absorption pathway. - Obesity: helps achieve clinically significant weight loss when combined with diet therapy. - Overweight: supports modest weight reduction as an adjunct to lifestyle modification. - Weight‑related comorbidities: contributes to improvement of risk factors such as elevated cholesterol and blood glucose.

Adverse reactions to Orlistat Polpharma are primarily related to its effect on fat digestion.

Common Side Effects: - Oily spotting on undergarments. - Fecal urgency or increased frequency. - Flatulence with oily discharge. - Abdominal cramping or discomfort. - Loose, oily stools. - Increased defecation volume.

Serious or Rare Side Effects: - Severe abdominal pain. - Persistent vomiting or diarrhea. - Pancreatitis. - Acute liver injury (rare). - Allergic reactions such as rash, pruritus or angioedema. - Steatorrhea leading to fat‑soluble vitamin deficiencies.

Before initiating therapy with Orlistat Polpharma, consider the following precautions: - Assess body mass index (BMI): confirm patient meets BMI criteria for obesity or overweight treatment. - Evaluate nutritional status: ensure adequate intake of vitamins A, D, E and K. - Monitor gastrointestinal health: avoid use in patients with chronic malabsorption syndromes. - Review concomitant medications: assess for potential interactions that may affect absorption of fat‑soluble drugs. - Counsel on low‑fat diet: advise patients to limit dietary fat to ≤30 g per meal to reduce side‑effects. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Orlistat Polpharma can affect the absorption of several co‑administered medicines.

Major Interactions (Avoid): - Cyclosporine: reduced systemic exposure may compromise transplant efficacy. - Levothyroxine: decreased absorption can lead to sub‑therapeutic thyroid levels. - Warfarin: altered vitamin K absorption may affect anticoagulation control.

Moderate Interactions (Monitor Closely): - Orally administered HIV protease inhibitors (e.g., ritonavir): monitor plasma concentrations. - Fat‑soluble vitamin supplements: may require dose adjustment or separate dosing timing. - Lipid‑lowering agents (e.g., fenofibrate): observe for changes in lipid profile.